ARTA
CRVS icon

A.R.T. Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

A.R.T. Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-17,497
Closed -$278K – 1422
2017
Q3 		$278K Buy
17,497
+1,101
+7% +$15.2K 0.01% 1037
2017
Q2 		$198K Buy
+16,396
New +$175K 0.01% 1162

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

A.R.T. Advisors's CRVS Position: Q4 2017 in Review

A.R.T. Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q4 2017, closing a stake of 17,497 shares — an estimated $278K sold.

A.R.T. Advisors first reported a position in CRVS in Q2 2017 and held it in 2 quarters. The position peaked at $278K in Q3 2017. 54 funds tracked by Wall St. Rank hold CRVS as of Q4 2017.

  • A.R.T. Advisors reported no remaining Corvus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 17,497 Corvus Pharmaceuticals shares in Q4 2017, an estimated $278K.
  • A.R.T. Advisors first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • A.R.T. Advisors's Corvus Pharmaceuticals position peaked at $278K in Q3 2017.
  • 54 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2017.

Based on A.R.T. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.